More recently, we reported that higher fasting WAT‐surface expression of LDLR and CD36 in subjects with overweight and obesity was positively associated with insulin resistance and plasma interleukin 1 receptor antagonist (IL‐1Ra) (Cyr et al., 2020), which is a measure of the systemic activation of the interleukin 1 (IL‐1) signaling (Bissonnette et al., 2015). Here, LDLR is linked to Insulin resistance.